Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty

NCT00041509 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00041509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00041509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2002
Completion date
May 31, 2003
Enrollment
343 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

arthroplasty